Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial

First randomised study of an ATR inhibitor (n=70) showed benefit of adding berzosertib to gemcitabine in this populaiton (median progression-free survival 22.9 vs. 14.7 weeks, HR 0.57; 90% CI 0.33–0.98; p=0.044), warranting further investigation in this setting.


The Lancet Oncology